WHO LAUNCHES FIRST TRIAL OF ANTIVIRAL TO PREVENT BUNDIBUGYO STRAIN OF EBOLA
Photo Credit:Getty Images
The first clinical trial is under way of an antiviral drug's effectiveness in people exposed to the deadly Ebola strain spreading in the Democratic Republic of Congo, the WHO said Tuesday.
The trial, called EBO-PEP, aims to assess the effectiveness of the antiviral obeldesivir in post-exposure prophylaxis, for people who have been in contact with confirmed Bundibugyo cases.
The experimental drug, which is administered orally and was developed by the US pharmaceutical firm Gilead Sciences, has shown efficacy in pre-clinical models against viruses in the wider family of filoviruses that cause haemorrhagic fevers.
Clinical trials mark the stage at which a promising drug is tested in humans.
World Health Organization Director-General Tedros Adhanom Ghebreyesus confirmed the launch of the trial in a post on X.
"Every breakthrough begins with hope," he wrote.
"If effective among high-risk contacts after exposure, this could mark a major step forward" in preventing contacts from developing disease, he added.
There are no approved vaccines or treatments for Bundibugyo.
According to the DRC's latest official figures, the rare Ebola species has infected more than 1,960 people and killed more than 700.
The outbreak was declared on May 15 after several deaths in Ituri, a mineral-rich north-eastern province plagued by armed groups.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have been found in five DRC provinces and in neighbouring Uganda.
But more than 90 per cent of cases are still being detected in Ituri.
The first patients for the obeldesivir trial are being recruited at PEP centres set up adjacent to the Ebola treatment centres operated by the Alliance for International Medical Action (ALIMA) NGO in Bunia and Rwampara, in Ituri.
It aims to recruit nearly 1,000 participants aged 12 and over who have been in direct contact with a confirmed case within the preceding five days but are not showing symptoms.
Each participant will be monitored daily for 21 days, with a final visit at 42 days.
